Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 4 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-30M | $-25M | $-35M | -8.4% | - | -60.1% |
| 2024 | $0M | $-65M | $-63M | $-54M | 66.7% | - | 905.6% |
| 2023 | $0M | $-1M | $-6M | $-12M | 18.2% | - | -56.3% |
| 2022 | $0M | $-12M | $-14M | $-3M | 49.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 0 |
| Operating Revenue | 0 |
| Operating Expense | 30.40 |
| Research And Development | 16.74 |
| Selling General And Administration | 13.66 |
| Total Expenses | 30.40 |
| Operating Income | -30.40 |
| Total Operating Income As Reported | -30.40 |
| EBITDA | -30.08 |
| Normalized EBITDA | -31.36 |
| EBIT | -30.40 |
| Interest Income | 3.92 |
| Interest Expense | - |
| Net Interest Income | 3.92 |
| Other Non Operating Income Expenses | - |
| Other Income Expense | 1.28 |
| Interest Income Non Operating | 3.92 |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | 3.92 |
| Pretax Income | -25.20 |
| Tax Provision | 0 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -25.20 |
| Net Income From Continuing And Discontinued Operation | -25.20 |
| Net Income From Continuing Operation Net Minority Interest | -25.20 |
| Net Income | -25.20 |
| Net Income Common Stockholders | -25.20 |
| Net Income Including Noncontrolling Interests | -25.20 |
| Normalized Income | -26.48 |
| Diluted NI Availto Com Stockholders | -25.20 |
| Basic Average Shares | 8.05 |
| Diluted Average Shares | 8.05 |
| Reconciled Depreciation | 0.32 |
| Total Unusual Items | 1.28 |
| Total Unusual Items Excluding Goodwill | 1.28 |
| Special Income Charges | - |
| Other Special Charges | - |
| Gain On Sale Of Security | 1.28 |
| General And Administrative Expense | 13.66 |
| Other Gand A | 13.66 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| LB Pharmaceuticals Incthis co. | LBRX | $829M | -32.88 | 2.75 | -8.4% | -19.35 |
| Arbutus Biopharma Corporation | ABUS | $859M | -25.65 | 11.22 | -43.7% | -25.48 |
| Theravance Biopharma, Inc. | TBPH | $844M | 7.97 | 2.84 | 35.7% | 5.34 |
| Janux Therapeutics, Inc. | JANX | $839M | -7.39 | 0.88 | -11.9% | -5.20 |
| ORIC Pharmaceuticals, Inc. | ORIC |
| $830M |
| -6.41 |
| 2.16 |
| -33.7% |
| -5.56 |
| Amphastar Pharmaceuticals, Inc. | AMPH | $825M | 8.41 | 1.05 | 12.4% | 6.17 |
| Sana Biotechnology, Inc. | SANA | $824M | -3.37 | 5.12 | -151.8% | -4.31 |
| Replimune Group, Inc. | REPL | $815M | -3.30 | 1.96 | -59.5% | -3.31 |
| Esperion Therapeutics, Inc. | ESPR | $806M | - | - | 7.5% | 13.94 |
| Peer Median | - | -3.37 | 2.16 | -22.8% | -3.81 | |